HOLMLUND JON T 4

4 · Galera Therapeutics, Inc. · Filed May 7, 2020

Form 4

Period: 2020-05-05

Chief Medical Officer

Transactions

Exercise/Conversion
Stock Option
2020-05-06−1,489→ 15,856 total
Exercise: $1.07Exp: 2023-01-22→ Common Stock (1,489 underlying)
Exercise/Conversion
Stock Option
2020-05-07−2,059→ 13,797 total
Exercise: $1.07Exp: 2023-01-22→ Common Stock (2,059 underlying)
Exercise/Conversion
Stock Option
2020-05-05−3,064→ 17,345 total
Exercise: $1.07Exp: 2023-01-22→ Common Stock (3,064 underlying)
Exercise/Conversion
Common Stock
2020-05-05$1.07/sh+3,064$3,278→ 3,064 total
Sale
Common Stock
2020-05-05$12.16/sh−3,064$37,258→ 0 total
Exercise/Conversion
Common Stock
2020-05-06$1.07/sh+1,489$1,593→ 1,489 total
Sale
Common Stock
2020-05-06$12.00/sh−1,489$17,868→ 0 total
Exercise/Conversion
Common Stock
2020-05-07$1.07/sh+2,059$2,203→ 2,059 total
Sale
Common Stock
2020-05-07$12.00/sh−2,059$24,709→ 0 total

Footnotes (4)

[F1]The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 18, 2019.
[F2]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $12.00 to $12.62. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F3]The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $12.00 to $12.05. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
[F4]The option has fully vested and is currently exercisable.

Documents

1 file